In this episode, we take a look at a company that’s on a mission to get safe, natural psychedelics into the hands of everyone who needs them, as soon as possible. Filament Health (FH.NEO) is an exclusively natural psychedelic drug development company and received the first-ever psilocybin extraction and standardization patent for a public company by the Canadian Intellectual Property Office. We analyze Filament’s future potential in the industry. Tune in!
Filament Health (FH.NEO) Leading the way in Natural Psychedelics. But Is it a Good Long Term Investment?
Latest Articles
- Soma Gold (SOMA.V): Fully funded, profitable, and undervalued
- BioNxt (BNXT.C) rips as European Patent Office backs Cladribine thin-film
- Video: Alta Copper CEO is buying ATCU as the stock rocks
- Prismo Metals (PRIZ.C) raises half a mill; now It’s time to put it to work
- NetraMark Holdings (AIAI.C): Failed FDA trials cost billions, NetraAI may prevent them
Top Searches
Abitibi Greenstone Belt Barrick Gold best canadian cannabis company biotech Bitcoin blockchain bullion Canada cannabis CBD China Chris Parry covid cryptocurrency DEFN.V Fraser Institute gambling Gold gold price. gold prices Greg Nolan hemp inflation interest rates investing investments lithium Lukas Kane marijuana mining money Newmont Goldcorp Nexus Gold pharmaceuticals psychedelics resources shrooms stock market stocks technology trading uranium wealth wealth creation weed
Leave a Reply